Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development Announce First Patient Dosed in ALETA-001 Phase 1/2 Clinical Trial in Patients with Relapsed/Refractory B-Cell Malignancies

Contributed by: Business Wire

Logo

Tags

Oncology

Health

Clinical Trials

Research

Science

Pharmaceutical

Biotechnology

Aleta Biotherapeutics and Cancer Research UK’s Centre for Drug Development

More Like This

PR Newswire associated0

AvenCell Announces First Patient Dosed in a Phase IA Study with lead product candidate AVC-201, a Novel Allogeneic CD123-Directed Switchable CAR-T Investigational Therapy for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia and other CD123 Hematological Malignancies

PR Newswire associated0

Atara Biotherapeutics and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel® Data in The Lancet Oncology

Egle Therapeutics to Share Preclinical Efficacy Data for EGL-001, a CTLA-4/CD25 Antagonist Fusion Protein at the Society for Immunotherapy of Cancer Meeting

Egle Therapeutics to present novel immunocytokine preclinical data for EGL-001 with poster presentation at the 2024 AACR Annual Meeting

Alentis Receives FDA Fast Track Designation for ALE.P02 for the Treatment of CLDN1+ Squamous Solid Tumors

Preliminary Clinical Data on Relma-Cel Injection in Adults with Active Systemic Lupus Erythematosus in China at the Eular 2024 Congress

PR Newswire associated0

Biosyngen's first-in-class CAR-T asset targeting solid tumors has entered pivotal phase II trial, Phase I trial data debut at ESMO 2024 Annual Congress

T-cell therapy developer, Cbio A/S Unveils 2023 Annual Report Amid Clinical Trial Preparations, Signaling Major Shift to Clinical Stage with DKK40M Financing Secured